- Home
- LU vs RYTM Comparison
LU vs RYTM Comparison
Compare LU & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LU
- RYTM
- Stock Information
- Founded
- LU 2005
- RYTM 2008
- Country
- LU China
- RYTM United States
- Employees
- LU N/A
- RYTM N/A
- Industry
- LU Finance: Consumer Services
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- LU Finance
- RYTM Health Care
- Exchange
- LU Nasdaq
- RYTM Nasdaq
- Market Cap
- LU 2.8B
- RYTM 3.2B
- IPO Year
- LU 2020
- RYTM 2017
- Fundamental
- Price
- LU $2.98
- RYTM $50.00
- Analyst Decision
- LU Hold
- RYTM Strong Buy
- Analyst Count
- LU 2
- RYTM 12
- Target Price
- LU $2.98
- RYTM $68.58
- AVG Volume (30 Days)
- LU 3.9M
- RYTM 541.5K
- Earning Date
- LU 04-21-2025
- RYTM 05-06-2025
- Dividend Yield
- LU 80.13%
- RYTM N/A
- EPS Growth
- LU N/A
- RYTM N/A
- EPS
- LU N/A
- RYTM N/A
- Revenue
- LU $4,671,260,668.00
- RYTM $130,126,000.00
- Revenue This Year
- LU N/A
- RYTM $45.46
- Revenue Next Year
- LU $1.48
- RYTM $63.04
- P/E Ratio
- LU N/A
- RYTM N/A
- Revenue Growth
- LU N/A
- RYTM 68.06
- 52 Week Low
- LU $2.00
- RYTM $35.17
- 52 Week High
- LU $4.94
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- LU 48.48
- RYTM 41.06
- Support Level
- LU $2.90
- RYTM $52.54
- Resistance Level
- LU $3.10
- RYTM $55.21
- Average True Range (ATR)
- LU 0.13
- RYTM 2.34
- MACD
- LU -0.03
- RYTM 0.10
- Stochastic Oscillator
- LU 25.05
- RYTM 0.34
About LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.